Abstract: The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

Abstract: The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.

Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Abstract: The present invention relates to use of the non-secretor/secretor blood group status of an individual as a criterion for need of Lactobacillus/LAB-enriched probiotic supplementation. The present invention relates also to method of assessing the need of an individual for Lactobacillus/LAB-enriched probiotic supplementation by determining the secretory blood group status of the individual.

Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Abstract: The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups.

Abstract: The present invention relates to a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. The present invention further relates to a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.

Abstract: The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.

Abstract: The present invention relates to an in vitro and/or ex vivo method of screening probiotic bacterial strains. The present invention also relates to a method of assessing quality of probiotic culture. In addition, the present invention relates to use of animal cells in screening of a probiotic strain. The present invention also relates to use of animal cells in assessing quality of probiotic culture.

Abstract: Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

Abstract: Provided is a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. Further provided is a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.

Abstract: Provided is a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. Further provided is a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.